Skip to main content
TipRanks
Go Ultimate75% OFF

Morepen Laboratories Limited (MOREPENLAB) AI Stock Analysis

14 Followers
IN:MOREPENLAB

Morepen Laboratories Limited

(NSE:MOREPENLAB)

Select Model
Rating:57Neutral
Price Target:INR 95.00â–²(4.80% Upside)
Action:reiterated
Date:09/17/26

The overall score of 57 reflects a company with a strong balance sheet and bullish technical momentum, but these are offset by significant fundamental weaknesses. The most impactful factor is the poor cash flow generation, with declining operating cash and deeply negative free cash flow, which raises sustainability concerns. Additionally, the high P/E ratio of 44.82 makes the stock look overvalued given its recent earnings decline. Positive price trends and a conservative capital structure provide some support, but the financial and valuation risks dominate the assessment.

Positive Factors
Revenue and earnings improvementThe combination of multi-year revenue growth and sustained positive net income indicates that Morepen has rebuilt operating momentum after the 2023 trough. Continued earnings generation can support reinvestment, strengthen financial resilience, and provide a foundation for compounding if the business maintains demand across its markets.
Negative Factors
Weak cash conversionPersistently negative free cash flow means reported earnings are not translating into internally generated cash at a sufficient level. This can constrain self-funded growth, increase reliance on financing or working-capital improvements, and reduce flexibility if operating requirements or investment needs remain elevated.

Morepen Laboratories Limited (MOREPENLAB) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%250%IN:MOREPENLAB+111.41%INDA-4.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 50.19B
Dividend Yield
0.22%
Average Volume (3M)
917.64K
Price to Earnings (P/E)
26.5
Beta (1Y)
0.81
Revenue Growth
30.20%
EPS Growth
91.17%
Country
India
Employees
2,152
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Morepen Laboratories Limited Business Overview & Revenue Model

Company Description

Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a...

Morepen Laboratories Limited Financial Statement Overview

Summary

Financial performance is mixed. The Income Statement (Score: 58) shows steady revenue growth and improving gross margins, but declining operating and net margins with a 20% drop in net income. The Balance Sheet (Score: 72) is strong with low leverage and a solid equity base, though ROE has fallen significantly. The Cash Flow Statement (Score: 35) is a major concern, with declining operating cash flow and deeply negative free cash flow due to heavy capex, raising liquidity risks. The overall financial picture is weighed down by poor cash generation.

Income Statement

58Neutral

Balance Sheet

72Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue22.86B18.06B18.30B17.02B14.18B15.42B
Gross Profit8.97B6.82B6.30B6.18B2.19B4.81B
EBITDA2.97B1.73B1.92B1.73B856.66M1.57B
Net Income1.89B948.77M1.18B961.60M386.75M1.02B
Balance Sheet
Total Assets23.06B19.36B17.78B12.93B11.10B10.70B
Cash, Cash Equivalents and Short-Term Investments2.71B916.99M1.27B169.45M216.66M158.03M
Total Debt3.23B2.08B1.05B289.99M251.64M1.33B
Total Liabilities9.24B6.89B5.91B4.46B3.58B4.92B
Stockholders Equity13.81B12.46B11.56B8.47B7.53B5.79B
Cash Flow
Free Cash Flow0-1.44B-919.76M-79.61M-1.37B-1.25B
Operating Cash Flow0162.28M320.57M733.75M-911.71M-577.58M
Investing Cash Flow0-1.22B-3.22B-833.00M-465.09M-316.79M
Financing Cash Flow01.13B3.00B52.05M1.44B663.34M

Morepen Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price90.65

Price Trends

50DMA116.37Negative
100DMA95.35Negative
200DMA68.65Positive

Market Momentum

MACD-7.60Positive
RSI35.58Neutral
STOCH14.99Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Negative. The current price of 90.65 is below the 20-day moving average (MA) of 105.89, below the 50-day MA of 116.37, and above the 200-day MA of 68.65, indicating a neutral trend. The MACD of -7.60 indicates Positive momentum. The RSI at 35.58 is Neutral, neither overbought nor oversold. The STOCH value of 14.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MOREPENLAB.

Morepen Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:MOREPENLAB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ALEMBICLTDIN:ALEMBICLTD69NeutralINR 28.62B8.07―2.16%-4.66%9.58%
IN:WINDLASIN:WINDLAS66NeutralINR 20.24B30.70―0.64%18.48%-0.41%
IN:HIKALIN:HIKAL57NeutralINR 27.35B-555.15―0.27%8.93%-149.51%
IN:MOREPENLABIN:MOREPENLAB57NeutralINR 49.67B26.46―0.22%30.20%91.17%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:SOLARAIN:SOLARA50NeutralINR 30.74B82.98――27.30%456.80%
IN:INDOCOIN:INDOCO43NeutralINR 21.54B68.55―0.09%10.75%―

* Healthcare Sector Average

Performance Comparison

0%100%200%IN:MOREPENLABIN:ALEMBICLTDIN:HIKALIN:INDOCOIN:SOLARAIN:WINDLASDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:MOREPENLAB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:MOREPENLABMorepen Laboratories Limited90.6547.59110.53%
IN:ALEMBICLTDAlembic Limited111.4416.0716.86%
IN:HIKALHikal Limited221.854.221.94%
IN:INDOCOIndoco Remedies Limited233.35-19.63-7.76%
IN:SOLARASolara Active Pharma Sciences Ltd.639.30116.9522.39%
IN:WINDLASWindlas Biotech Ltd.980.80213.4027.81%

Morepen Laboratories Limited Corporate Events

Morepen Launches First U.S. Prescription Generic, Expanding Beyond APIs

Nov 9, 2026

Morepen Laboratories has launched Desloratadine Tablets USP, 5 mg, as its first U.S. prescription generic through wholly owned subsidiary Morepen Bio Inc. Available in 100-count and 500-count packs, the product builds on the company’s established sup...

Morepen Files First U.S. ANDA to Bolster Integrated CDMO Platform

Sep 28, 2026

Morepen Laboratories has filed its first Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sitagliptin Tablets USP in three strengths, marking its entry into U.S.-bound finished dosage submissions. The move extends its C...

Morepen Laboratories posts e‑voting results for 41st AGM

Sep 26, 2026

Morepen Laboratories Limited has reported the e‑voting results for its 41st Annual General Meeting held on September 26, 2026 via video conferencing and other audio‑visual means. The company provided remote and AGM e‑voting facilities in line with Co...

Morepen Laboratories Publishes AGM and Dividend Notice for Investors

Aug 26, 2026

Morepen Laboratories Limited has informed the stock exchanges that it published newspaper notices regarding its 41st Annual General Meeting, dividend declaration and the associated record date. The disclosures appeared in the Financial Express and Ja...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 17, 2026